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ABSTRACT
One of the regenerative periodontal treatments for infrabony pocket is open flap debridement (OFD) with the addition of 
growth factor derived from platelet concentrate. Advanced platelet-rich fibrin (A-PRF) is a further development of platelet-
rich fibrin (PRF) with a lower centrifugation speed (1,500 rpm, 14 minutes). The purpose of this study was to examine 
the differences in periodontal tissue regeneration after the application of A-PRF and PRF in the treatment of infrabony 
pockets evaluated from probing depth (PD), relative attachment loss (RAL), and alveolar bone height. The samples were 
taken from 20 infrabony pockets divided into 2 groups: 10 subjects were treated with OFD+A-PRF and OFD+PRF on the 
remaining subjects. Probing depth (PD) and relative attachment loss (RAL) measurement were performed on days 0, 30, 
and 90. Bone height measurements were performed using CBCT X-rays on days 0 and 90. The results showed that PD 
and RAL reduction in the group of OFD+A-PRF was significantly greater than that in the OFD+PRF group. Bone height 
reduction in both groups showed no difference. The conclusion obtained from this study is A-PRF application enhances 
periodontal tissue regeneration by generating greater probing depth and relative attachment loss reduction compared to 
PRF, as well as an increase in bone height similar to in the treatment of infrabony pockets.
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INTRODUCTION
Periodontitis is an inflammatory disease of 
periodontal tissue that results in damage to 
periodontal ligament and alveolar bone.1 One of the 
clinical signs of periodontitis is the presence of a 
periodontal pocket. Periodontal pockets are divided 
into suprabony pocket and infrabony pocket. 
Infrabony pocket is a pocket with base of the sulcus 
more apical than alveolar bone, in general there is 
vertical or angular defect.2,3
Treatment of periodontitis includes surgical 
and non-surgical treatment.4 Surgical treatment 
is performed when inflammation persists after 
non-surgical treatment.5 One of the periodontal 
surgical treatments is an open flap debridement 
(OFD) aimed at removing focal infection,6 but 
could unable to regenerate tissue damaged by 
periodontal disease.7 The result of OFD treatment 
is the formation of long junctional epithelium.8
The primary goal of periodontal treatment 
is to regenerate periodontal tissue.9 Periodontal 
tissue regeneration is the formation of new bone, 
cementum, and new periodontal ligaments on 
tooth root surfaces that are damaged to restore 
anatomy and function.10 The clinical parameters for 
evaluating the success of periodontal regeneration 
are probing depth (PD), attachment loss, and 
bone height.8 Bone height can be seen through 
radiographic examination starting after 3 months.11
Ideal periodontal tissue regeneration is to 
improve periodontal and bone attachment, reduce 
pocket depth, and little gingival recession.12 Some 
types of regenerative periodontal treatment are: root 
conditioning, addition of bone graft, guided tissue 
regeneration (GTR), a combination of GTR-bone 
graft, and the addition of growth factor.13 Growth 
factors that contribute to periodontal regeneration 
include platelet-derived growth factor (PDGF), 
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transforming growth factor (TGF-β), and insulin-like 
growth factor (IGF).14
The use of PRF in OFD treatment is to 
enhance tissue regeneration in the treatment of 
infrabony pocket.15 Platelet rich fibrin (PRF) is a 
second-generation platelet concentrate16 which is 
processed with whole blood taken from a patient 
fed into a 10 ml tube and centrifuged immediately 
at 2,700 rpm, 12 mins, with PRF results in clot in 
the middle between acellular plasma and red blood 
cells.17,18,19
Platelet rich fibrin contains leukocytes, 
platelets, and growth factors contained in a three-
dimensional fibrin matrix that acts as a scaffold,20 
thereby slowing the release of growth factors during 
wound healing.16 Some growth factors that can 
be found in PRF include PDGF, vascular endotel 
growth factor (VEGF), TGF-β, IGF-1, IGF-2, and 
epidermal growth factor (EGF).20,21
Some clinical applications of PRF are socket 
preservation after extraction, gingival recession 
treatment, infrabony defect regeneration, and 
sinus elevation.15 Treatment of infrabony defects 
by combining OFD and PRF gives better results 
than OFD alone.22 A study showed that the 
administration of demineralized freeze-Ddied bone 
allograft (DFDBA) as graft material in the treatment 
of infrabony pockets gave no significant difference 
with PRF.10
Advanced platelet-rich fibrin (A-PRF) is a 
further development of PRF by using the concept 
of lower rotational speed. A research on the 
effect of centrifugation forces on PRF protocol 
showed centrifugation pressure has an effect 
on cell distribution.23 Leukocytes in the PRF are 
mostly present at the bottom of the tube, due 
to centrifugation pressure. The procedure of 
preparing A-PRF by converting the centrifugation 
process to 1,500 rpm for 14 minutes shows more 
evenly distributed granulocyte neutrophils16 and 
looser fibrin matrix. Neutrophil granulocytes have 
soft and hard tissue regeneration capabilities, direct 
monocytes to phagocytosis, and produce proteases 
such as MMP9 for wound healing process.23
A study comparing growth factor release 
in PRP, PRF, and A-PRF concluded that A-PRF 
released significantly more total factor growth than 
PRF.15 A research comparing PRF and A-PRF is 
limited to laboratory and animal studies, so further 
research with human subjects is needed.
MATERIALS AND METHODS
The type of research conducted was quasi expe-
rimental with independent variables OFD+A-PRF 
and OFD+PRF on the treatment of infrabony pocket 
with observation time of day 0 (baseline), day 30, 
and day 90. Dependent variables were PD, RAL, 
and alveolar bone height.
After obtaining signed informed consent and ethical 
clearance (No.001220/KKEP/FKG-UGM/EC/2017), 
20 infrabony pockets were divided into 2 groups, 
10 subjects were treated with OFD+A-PRF and 
OFD+PRF on the other group. Periodontal depth 
and RAL measurements were performed on days 
0, 30, and 90. Bone height measurements were 
performed using CBCT X-rays on days 0 and 90. 
Initial data collection of PD and RAL 
measurements was performed on the treated tooth. 
Probing depth was measured from the distance 
between gingival margin and sulcus, RAL was 
measured from cementoenamel junction (CEJ) 
and sulcus. CBCT X-ray was taken as initial data, 
then alveolar bone height was measured from the 
distance between CEJ to the most apical base of 
the defect from the vertical direction of the bone.
Periodontal flap surgical procedures began 
with local anesthesia, injected after the surgical 
area was disinfected. Full vertical and sulcular full 
thickness flap incisions were performed, flaps were 
observed and debridement was performed in the 
defect areas with SRP and curettage. Tetracycline 
HCl 75 mg/ml solution was applied to a hard tissue 
with sterile pellet cotton for 3 minutes which was 
changed every 30 seconds, and rinsed with distilled 
water.
Ten milliliter intravenous blood was taken and 
centrifuged according to their respective groups, 
A-PRF (1,500 rpm, 14 mins) and PRF (2,700 rpm, 
12 mins). A-PRF and PRF clots were taken, partially 
clot was compressed on PRF box to membrane 
with its exudate called releasate. Clot, membrane, 
and releasate were applied to the infrabony defect. 




The flap was returned and sutured, then covered 
with a periodontal pack. Patients were given 
antibiotics, analgesics and anti-inflammatory. The 
patients were given postoperative instructions 
and explanation how to maintain tooth and mouth 
health after surgery. Control was done 7 days later 
to remove the periodontal pack. Control of oral 
hygiene and wound healing was done once a week 
for 4 weeks after the OFD.
RESULTS
Table 1 shows that the mean of PD decreased on 
day 30 and day 90 (after treatment). The mean 
reduction of PD after treatment (day 30 and 90) 
was greater in the OFD + A-PRF group than that 
in the OFD + PRF group. The initial values of PD 
measurement were different between the two 
treatment groups, so it is necessary to ascertain the 
magnitude of the reduction difference of PD in each 
group for further significance test.
The data in Table 2 show that the mean of PD 
reduction in the OFD + A-PRF group was greater 
than that in the OFD + PRF group on days 0-30, 
30-90, and 0-90. The largest PD reduction was in 
the OFD + A-PRF group on days 0-90.  
Mann-Whitney U test of PD reduction on days 
30-90 showed no significant difference between 
the groups of OFD + PRF and OFD + A-PRF. 
Examination on days 0-30 and on days 0-90 showed 
a significance difference. Table 3 shows that PD 
reduction in A-PRF was significantly greater than 
that in PRF.
Table 4 shows that the mean of RAL decreased 
on day 30 and day 90 (after treatment). The mean 
of RAL reduction after treatment (30th and 90th day) 
was greater in the OFD + A-PRF group than that 
in the OFD + PRF group. The initial values of RAL 
measurements were different between the two 
treatment groups, so it is necessary to see the 
magnitude of the RAL reduction difference in each 
group for subsequent significance tests.
The data in Table 5 show that the mean of 
RAL reduction in the OFD + A-PRF group on days 
0-30, 30-90, and 0-90 was greater than that in the 
OFD + PRF group. The mean of RAL reduction 
on days 0-30 in both groups was greater than the 
mean of RAL reduction on 30-90 days. The mean 
of RAL reduction was the highest on days 0-90 with 
mean and standard deviation of 3.40 ± 1.26 mm.
Mann Whitney U test results on RAL reduction 
on days 30-90 showed a significance value ofp> 0.05 
which means there was no significant difference 
in RAL reduction between OFD + PRF group and 
OFD + A-PRF group on days 30-90. The results 
on days 0-30 and 0-90 showed p value <0.05. The 
table above shows that RAL reduction on A-PRF 
was greater than that of PRF significantly.
Table 7 shows alveolar bone height rate 
impro ved in the OFD + PRF group and the 
OFD + A-PRF group on day 90. Improved bone 
height was higher in the OFD + A-PRF group. Bone 
height improvement can be seen in Figure 1. 
The significance level of parametric Paired 
T-test obtained p value <0.05, indicating that there 
was significant alveolar bone height improvement 
between the observation time in each group. The 
initial values of alveolar bone height measurements 
between the two treatment groups were different. 
Therefore it was necessary to see the difference 
in alveolar bone height reduction in each group for 
subsequent significance tests.
Table 1. Mean and standard deviation of probing depth (PD) (mm)
Time n OFD + PRF OFD + A-PRF
Day-0 10 5.20 ± 0.92 5.10 ± 0.99
Day-30 10 3.70 ± 0.95 3.00 ± 1.15
Day-90 10 2.50 ± 0.71 1.30 ± 0.48
Table 2. Mean and standard deviation of probing depth (PD) 
reduction (mm)
Time n OFD + PRF OFD + A-PRF
Day 0 - 30 10 1.50 ± 0.53 2.10 ± 0.57
Day 30 - 90 10 1.20 ± 0.92 1.70 ± 0.95
Day 0 - 90 10 2.70 ± 0.95 3.80 ± 0.92
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Table 4. Mean and standard deviation of relative attachment 
loss (RAL) (mm)
Time n OFD + PRF OFD + A-PRF
Day-0 10 12.80 ± 1.40 12.10 ± 1.10
Day-30 10 11.90 ± 1.91 10.30 ± 1.42
Day-90 10 10.60 ± 1.43 8.70 ± 1.06
Table 5.  Mean and standard deviation of relative attachment 
loss (RAL) reduction
Time n OFD + PRF OFD + A-PRF
Day  0 - 30 10 0.90 ± 0.74 1.80 ± 0.79
Day 30 - 90 10 1.30 ± 0.82 1.60 ± 1.51
Day  0 - 90 10 2.20 ± 0.79 3.40 ± 1.26
Table 6. Mann-Whitney U test result of relative attachment loss 
(RAL) reduction 
Observation time p
Day 0 - 30 0.024*
Day 30 - 90 0.440
Day 0 - 90 0.040*
*: significant
Table 7. Alveolar bone height mean and standard deviation (mm)
Time n OFD + PRF OFD + A-PRF
Day-0 10 5.74 ± 0.86 5.08 ± 0.74
Day-90 10 4.69 ± 0.99 3.77 ± 0.77
Table 10. Results of parametric independent t-test on alveolar 
bone height reduction between treatment groups
Observation time p
Day 0 - 90 0.355
The results of independent t-test on alveolar 
bone height reduction showed a significance value 
of p> 0.05, indicating there was no significant 
difference in alveolar bone height improvement 
between the OFD + PRF group and the 
OFD + A-PRF group.
DISCUSSIONS
The results showed PD and RAL reduction in 
the OFD+A-PRF and OFD+PRF groups at each 
observation time, on day 30 and day 90. This means 
there was an improvement in clinical conditions. 
Attachment loss is the distance between the base 
of the pocket with a CEJ or point and is generally 
related to probing depth, although it is not always 
the case. Reduced attachment loss values indicate 
a periodontal tissue repair.2
PD and RAL reduction is influenced by growth 
factor produced by PRF and A-PRF, such as PDGF, 
EGF, and IGF-1 which act as homeostasis factor, 
increase proliferation and migration of periodontal 
fibroblasts, and prevent periodontal fibroblas 
apoptosis.1,24 The results of PD and RAL reduction 
between the two groups indicated a significantly 
greater PD and RAL reduction in the OFD+A-PRF 
group on days 0-30 and days 0-90. The reduction 
of the OFD+A-PRF group was significantly higher 
because the total number of growth factors produced 
by A-PRF was significantly higher than that of 
PRF.15 This allows for better tissue regeneration in 
both A-PRF groups. As is known, PDGF, VEGF, and 
IGF-1 increase the proliferation of fibroblasts and 
angioblasts, the synthesis of extracellular matrix, 
and angiogenesis process.25 More neutrophil 
granulocytes in A-PRF also affects macrophage 
differentiation, resulting in the regeneration of hard 
and soft tissues.16
The results of PD and RAL reduction between 
the OFD+A-PRF and OFD+PRF groups on days 
30-90 did not show any significant differences. This 
is probably due to the fact that healing process 
Figure 1. Alveolar bone height difference on day 0 and 90
Table 8.  Parametric paired t-test results on alveolar bone 
height in each treatment group
Group p
OFD + PRF 0.000 Significant
OFD + A-PRF 0.000 Significant
Table 9. Mean and standard deviation of alveolar bone reduc-
tion (mm)
Time n OFD + PRF OFD + A-PRF
Day 0 - 90 10 1.04 ± 0.49 1.32 ± 0.78




enters tissue maturation process. As is known, 
the post-surgical treatment of periodontal surgery 
begins with an inflammatory process lasting up to 
two days postoperatively. On day 4, proliferation of 
fibroblasts and angioblasts occurs, followed by the 
formation of new junctional epithelium at the end of 
the 2nd week. In the end of week 4 to month 3, the 
process of tissue maturation and bone remodeling 
occurs.26
The results of alveolar bone height 
measurements obtained in this study between A-PRF 
and PRF applications was not significantly different. 
The median data showed an improvement in bone 
height on day 90 in both groups. This can be seen 
from the bone height on day 90 which was smaller 
than bone height on day-0 (baseline). The OFD+A-
PRF group and the OFD+PRF group showed 
similar patterns of bone height improvement. Bone 
regeneration is affected by the association between 
RANK and RANKL or OPG. RANK binding to OPG 
may inhibit osteoclast activation and differentiation 
processes and increase osteoblast proliferation.2 
The results suggest that PRF and A-PRF may 
increase OPG secretion.27,28
Alveolar bone height reduction results showed 
a higher alveolar bone improvement in the OFD+A-
PRF group compared to the OFD+PRF group. 
This is because in the process of A-PRF with lower 
centrifugation, the number of leukocytes obtained 
was higher because it did not sediment to the bottom 
of tube.23 Leukocytes play an important role in bone 
healing, especially macrophages. Macrophages 
improve the differentiation of osteoblasts that 
increase bone formation, and promote tissue 
integration. Leukocytes also prevent pathogen 
infiltration thereby reducing the risk of infection.16
The number of growth factors produced 
by A-PRF, such as PDGF, TGF, and VEGF, was 
significantly higher than that by PRF.15 VEGF plays 
an important role in the process of angiogenesis 
that stimulates the proliferation and migration of 
endothelial cells and maintains blood vessels 
formation. VEGF also plays a role in bone formation 
by increasing the migration, proliferation, and 
differentiation of osteoblasts. PDGF helps tissue 
regeneration and increases osteoblast precursor 
cells to stimulate bone regeneration.29 TGF 
increases the proliferation of mesenchymal cells, 
collects osteoblast precursor cells, and osteoblast 
differentiation.30
The alveolar bone height reduction difference 
between the OFD + PRF group and the OFD + A-PRF 
group showed no significant improvement in bone 
height, in line with a study of rabbit subjects. This 
can be due to several things, among others, PRF 
has a stronger structure than A-PRF when formed 
into membranes. The A-PRF membrane dissolves 
from day 3, in contrast to the PRF membrane which 
can last up to 7 days. Total volume of PRF obtained 
after centrifugation is greater ± 30% than that of 
A-PRF. Based on histological examination, Bone 
Morphogenetic Protein (BMP)-2 was not found 
in the A-PRF group, whereas BMP-2 was found 
in the PRF group.28 Bone Morphogenetic Protein 
(BMP)-2 serves to improve osteoblast differentiation. 
In addition, the interaction between VEGF and 
BMP-2 may enhance the osteogenic effects of 
BMP-2.29
CONCLUSION
Based on the results of the study, it is concluded 
that periodontal tissue regeneration after APRF 
application seen from PD and RAL reduction is 
greater than that after PRF application on the 
treatment of infrabony pocket but there is no 
difference in alveolar bone height improvement.
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